99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
Recruiting · NCT06419348 · Interventional (participants receive a specific treatment) · Lead sponsor: First Affiliated Hospital of Chongqing Medical University
View the official record on ClinicalTrials.gov →Interventions studied
99mTc-QULIC-5-P1
What this trial is about
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- At least 18 years of age.
- Signed informed consent.
- Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
Exclusion criteria
- Patients with PSMA negative expression.
- Patients with pregnancy.
- The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
- Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components.
- Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Where it is running
1 location listed.
- The First Affiliated Hospital of Chongqing Medical University - Chongqing, Chongqing Municipality, China